Anna Poullard

Dec 19, 2023 | cell.com | Mohamed A. Gouda |Mark E. Zafereo |Mimi I. Hu |Anna Poullard

Management of common and serious adverse eventsSide effects due to RET inhibitors vary according to the used agent but are usually more tolerable than those caused by non-selective RET inhibitors (Figure 2). 9Subbiah V. Cassier P.A. Siena S. Garralda E. Paz-Ares L. Garrido P. Nadal E. Vuky J. Lopes G. Kalemkerian G.P. et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat. Med.